Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance

Busto-Leis, Jose Manuel; Servera-Negre, Guillermo; Mayor-Ibarguren, Ander; Cudós, Elena Sendagorta; Feito-Rodríguez, M.; Nuño-González, Almudena; Montero-Vega, María Dolores; Pinto, Pedro Herranz

doi:10.1111/jdv.17301

Cited by 32 publications

(46 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This suppressed and dysregulated immune state may trigger the reactivation of latent viral infections, such as HHV 6 and HHV 7 [ 10 ] . Factors supporting the viral reactivation theory include positive tissue immunohistochemistry, the detection of in situ viral mRNA, and IgG antibodies against HHV 6/7 [ 1 ] . Moreover, the detection of the SARS-CoV-2 virus spike protein on endothelial cells and lymphocytes indicates a direct correlation between COVID-19 infection and PR [ 3 ] .…”

Section: Discussionmentioning

confidence: 99%

“…The efficacy and safety of COVID-19 vaccines are currently a scientific priority. A large body of evidence has emerged in late 2021 to show that SARS-CoV-2 infection and COVID-19 vaccines are associated with skin disorders, including pityriasis rosea (PR) and pityriasis rosea-like eruptions (PR-LE) [ 1 – 6 ] . Vaccination-induced cases of PR by other vaccines have also been reported in the past[ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…The precise etiopathogenesis of PR remains largely unknown and its etiology is hypothesized to be multifactorial, including both infective and non-infective factors, such as autoimmunity and atopy [ 1 , 8 ] . The activation of immunological mechanisms triggers PR in both cases: infection and vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pityriasis Rosea Induced by COVID-19 Vaccination

Khattab

Christaki

Pitsios

2022

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

It is increasingly recognized that SARS-CoV-2 infection and COVID-19 vaccines have been associated with skin disorders, including pityriasis rosea. It has been reported that pityriasis rosea has been triggered by several vaccines, as a rare side-effect. We present two cases of COVID-19 vaccine-induced pityriasis rosea. Skin lesions appeared in a 49-year-old female 8 days after the first dose of the BNT162b2 mRNA vaccine and in a 53-year-old male 7 days after the second dose of the same vaccine. The exanthem was self-limited in both patients over a period of a month.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pityriasis Rosea Induced by COVID-19 Vaccination

Khattab

Christaki

Pitsios

2022

European Journal of Case Reports in Internal Medicine

View full text Add to dashboard Cite

show abstract

“…PR is a self-limiting pale exanthema along the Langer lines that originates from a preceding herald patch and commonly affects adolescents and young adults. It supposedly arises in the course of reactivation of human herpes virus 6 or 7 (HHV6/7); however, there are reports about development of PR both with COVID-19 infection and with COVID-19 vaccines, as published by Busto-Leis et al [59]. Notably, both mRNA vaccines and viral vector vaccines seem to be potential causative agents.…”

Section: Pityriasis Rosea (Pr)mentioning

confidence: 99%

“…As with the etiology of PR itself, COVID-19-associated and COVID-19-vaccine-associated PR remain largely unexplained phenomena to date. Pre-existing immunity towards seasonal respiratory coronaviruses might designate "COVID-19-PR" as a paraviral epiphenomenon comparable to PR with HHV6/7 reactivation [59].…”

Section: Pityriasis Rosea (Pr)mentioning

confidence: 99%

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

et al. 2021

View full text Add to dashboard Cite

(1) Background: Numerous vaccines are under preclinical and clinical development for prevention of severe course and lethal outcome of coronavirus disease 2019 (COVID-19). In light of high efficacy rates and satisfactory safety profiles, some agents have already reached approval and are now distributed worldwide, with varying availability. Real-world data on cutaneous adverse drug reactions (ADRs) remain limited. (2) Methods: We performed a literature research concerning cutaneous ADRs to different COVID-19 vaccines, and incorporated our own experiences. (3) Results: Injection site reactions are the most frequent side effects arising from all vaccine types. Moreover, delayed cutaneous ADRs may occur after several days, either as a primary manifestation or as a flare of a pre-existing inflammatory dermatosis. Cutaneous ADRs may be divided according to their cytokine profile, based on the preponderance of specific T-cell subsets (i.e., Th1, Th2, Th17/22, Tregs). Specific cutaneous ADRs mimic immunogenic reactions to the natural infection with SARS-CoV-2, which is associated with an abundance of type I interferons. (4) Conclusions: Further studies are required in order to determine the best suitable vaccine type for individual groups of patients, including patients suffering from chronic inflammatory dermatoses.

show abstract

Atypical pityriasis rosea associated with mRNA COVID‐19 vaccine

Bostan

Jarbou

2021

Journal of Medical Virology

View full text Add to dashboard Cite

Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance

Cited by 32 publications

References 10 publications

Pityriasis Rosea Induced by COVID-19 Vaccination

Pityriasis Rosea Induced by COVID-19 Vaccination

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

Atypical pityriasis rosea associated with mRNA COVID‐19 vaccine

Contact Info

Product

Resources

About